$ALXO News

ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript

ALX Oncology Holdings Inc. 2026 Q1 - Results - Earnings Call Presentation

ALX Oncology Q1 Earnings Call Highlights

ALX Oncology Holdings Inc (NASDAQ:ALXO) Beats Q1 Estimates and Unveils Promising Breast Cancer Data

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology Holdings Q1 Adj. EPS $(0.15) Beats $(0.22) Estimate

Favourable Signals For ALX Oncology Holdings: Numerous Insiders Acquired Stock

ALX Oncology To Present New Data From Phase 1b/2 Clinical Trial Evaluating Investigational CD47-Inhibitor Evorpacept In Combination With Jazz's Zanidatamab In HER2-Positive mBC At ESMO Breast Cancer 2026 Congress

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?

ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

ALX Oncology Appoints Jeff Knight As COO And Chief Development Officer, Effective April 13, 2026

ALX Oncology Appoints Jeff Knight As COO And Chief Development Officer, Effective April 13, 2026

Wells Fargo Initiates Coverage On ALX Oncology Holdings with Overweight Rating, Announces Price Target of $5

IBRX Stock Jumps on Progress in NK Cell Therapy Production

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4

HC Wainwright & Co. Reiterates Buy on ALX Oncology Holdings, Maintains $4 Price Target

ALX Oncology initiated with a Buy at UBS

ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 Update

ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones